← Back to patent-cliff list
Simepdekinra
Tier C — Watch / tradeSimepdekinra
Dice Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：IL17A
Indications (approved)：Plaque psoriasis, 免疫紊乱
Regional status
US
Phase II
2024-10-25
EU
Phase II
2024-10-25
China
-
Japan
Phase II
2024-10-25
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Simepdekinra?
Approved indications include: Plaque psoriasis, 免疫紊乱.
When does the Simepdekinra patent expire?
No public expiry year is available for Simepdekinra yet; this page updates once verified.
How do I get a quote for Simepdekinra intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01